• Caciane Portela Sousa and Carlos Brites.
• Universidade Federal do Piauí, Centro de Ciências da Saúde, Departamento de Parasitologia e Microbiologia, Teresina, PI, Brazil. Electronic address: portelasousa@ufpi.edu.br.
• Braz J Infect Dis. 2020 Sep 1; 24 (5): 428-433.

BackgroundThere is scarce information on the human immune response to the SARS-CoV-2 infection, and on the exacerbated inflammatory reaction observed in severe COVID-19 cases.ObjectiveTo review the available evidence on the role of interferons type I and type III to SARS-CoV-2 infection.MethodsWe reviewed the available published evidence on the role of immune response to SARS-CoV-2 infection as well as recent publications on characteristics and outcomes of COVID-19, and their relationship with interferons type I and type III.ResultsThe available data indicates that immune response plays an important role in controlling SARS-CoV-2 infection and the immune dysregulation can significantly modify the clinical outcomes of affected patients. In addition, the evidence suggests that IFN type I and III can play an important role in controlling viremia and modulating the immune response in COVID-19.ConclusionsDue to their central role in immune response against SARS-CoV-2 infection, IFN type I and III could be considered for treatment of COVID-19.Copyright © 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.

12 keywords...

hide…